Get notified when LSH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Material Weakness (unchanged) — Company continues to report identical material weaknesses in segregation of duties and written accounting policies with no remediation progress for second consecutive year.
revenue $1.3M, net income $142,408. Lakeside exits U.S. freight business, pivots to China pharma; loan drives liquidity
Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read
Key Changes
-
high
Company sold its U.S. freight-forwarding business (ABL Chicago) in Feb 2026 for $1, exiting cross-border logistics entirely to focus solely on pharmaceutical distribution in China—a fundamental strategic pivot.
MD&A: Disposal of ABL Chicago verify on EDGAR → -
high
Pharmaceutical revenue surged quarter-over-quarter to $1.3M, driven by customer expansion (4 to 12 active accounts) and higher infusion product sales; business launched Dec 2024 and now represents 100% of continuing operations.
MD&A: Pharmaceutical Revenue Growth verify on EDGAR → -
high
Company holds $8.7M loan receivable (49% of current assets) from single third party, maturing July 2026; management states ability to fund operations is 'partially dependent' on timely collection, creating material concentration risk.
MD&A: Loan Receivable Concentration verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
Partner
Trade LSH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify